Drawing for ALZSTATIN

USPTO serial 87898495

ALZSTATIN

Reviewed by CopyMark Law Group

Reg. 5837372Status 701Registered
Filing date
Status date
Registration date
Aug 20, 2019
Examiner
HETZEL, DANNEAN
Law office
Historical data usage

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with ALZSTATIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Trevor P. Schmidt

Trevor P. Schmidt Hutchison PLLC701 Corporate Center DriveSuite 250Raleigh, NC 27607

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical, veterinary and medical preparations for treating Alzheimer's, cognitive disorders, traumatic brain injury, sleep apnea and Parkinson's disease; Pharmaceutical substances for treatment and easement of Alzheimer's disease, only for human use ]ACTIVE—
042Development of pharmaceutical substances for treatment and easement of Alzheimer's disease, only for human use; Scientific and technological services, namely, conducting early evaluations in the field of new pharmaceuticals, pharmaceutical drug development services, pharmaceutical product evaluation and pharmaceutical research and development; scientific research and design, namely, scientific research in the field of pharmaceuticals; Research in relation to pharmaceuticals; Research and development of vaccines and medicines; Conducting early stage evaluations in the field of new pharmaceuticals; Pharmaceutical drug development services; Drug discovery services; Technical data analysis services, namely, data analysis through data mining; Computer-supported technical analysis services, namely, chemical analysis, and data analysis through data miningACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 18, 2025NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Nov 18, 20258.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Nov 17, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 21, 2025ES8RTEAS SECTION 8 RECEIVED—
Aug 20, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 22, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 22, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 22, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 20, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 4, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 4, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 15, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 25, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 25, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Apr 25, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Apr 25, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Apr 25, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 27, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 27, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Feb 27, 2019CNSLSUSPENSION LETTER WRITTEN—
Feb 27, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 27, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 27, 2019ALIEASSIGNED TO LIE—
Feb 22, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 22, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 22, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 22, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 16, 2018DOCKASSIGNED TO EXAMINER—
May 7, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 1, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance